We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Informatics

Informatics

Circio

Circio Holding ASA is a biotechnology company developing novel circular RNA and immunotherapy medicines. Circio has established a unique circular RNA (circRNA) platform to develop novel circRNA medicines for rare disease, vaccines and cancer. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA and viral vectors, which can be deployed for many purposes.

Latest Content

DNA double helix molecular structure illustration representing genetic code and biotechnology research.

Circular RNA Platform Boosts Gene Therapy Expression

Researchers demonstrate that a circular RNA-based AAV platform significantly enhances gene expression in vivo compared with conventional mRNA approaches.

Circular RNA strand illustrating RNA structure and gene expression.

Circio and UTMB Jointly Announce Collaboration To Evaluate circVec

Circio Holding ASA and the University of Texas Medical Branch are collaborating to develop circular RNA circVec vectors that enable months-long protein expression, aiming to deliver durable passive protection against high-risk viral pathogens.

Scientist adjusting microscope to examine petri dish sample in a laboratory focused on cell therapy research.

Circular RNA Innovator Circio Presents Strengthened circVec Gene Therapy Data at ASGCT 2025

Circio Holding ASA (OSE: CRNA), announces the presentation of new and strengthened in vivo data at the American Society of Gene and Cell Therapy (ASGCT) annual meeting 2025 in New Orleans, USA.

Double helix structure of DNA in a test tube.

Circio Announces Strengthened In Vivo Data and Enhanced circVec 2.2 Design

circVec 2.1 DNA vectors have now demonstrated higher and more durable expression vs. conventional mRNA-based expression in vivo for up to five months.

A test tube held in front of a DNA model.

Circio Presents Pre-Clinical Proof-of-Concept Data for Its circVec Gene Therapy Platform at the ASGCT 2024 Meeting

Two posters demonstrate in vivo superiority of circular RNA vs. linear mRNA-based expression and technical proof-of-concept for Circio´s ´remove-&-replace´ gene therapy format for the unmet medical need AATD.

Strand of orange mRNA on a blue background.

Industry Insight

Harnessing the Therapeutic Potential of Circular RNA

In this interview, Erik Digman Wiklund tells us about the discovery of circRNA and discusses some of the challenges of harnessing its full potential for therapeutic interventions.

Advertisement

Advertisement

Decoratvive background images

Never miss a story

with the Breaking Science News daily newsletter